Cancer treatment and research communications最新文献

{"title":"Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer","authors":"Zoran Andric ,&nbsp;Fedor Moiseenko ,&nbsp;Tamta Makharadze ,&nbsp;Alona Oleksiienko ,&nbsp;Eduardo Yañez Ruiz ,&nbsp;SungHyun Kim ,&nbsp;KeumYoung Ahn ,&nbsp;TaeHong Park ,&nbsp;Hana Ju ,&nbsp;Eric Hyungseok Baek ,&nbsp;Soonbum Kwon ,&nbsp;IlSung Chang ,&nbsp;SinHye Kim ,&nbsp;HyunAh Kim ,&nbsp;EunKyung Lee ,&nbsp;Claire Verschraegen","doi":"10.1016/j.ctarc.2025.100970","DOIUrl":"10.1016/j.ctarc.2025.100970","url":null,"abstract":"<div><h3>Purpose</h3><div>Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective response rate (ORR) during induction treatment in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). We now present long-term findings.</div></div><div><h3>Methods</h3><div>In this randomized, double-blind, multicenter phase 3 study, patients with metastatic or recurrent non-squamous NSCLC received CT-P16 or EU-bevacizumab (15 mg/kg every 3 weeks; ≤6 cycles) together with paclitaxel (200 mg/m²) and carboplatin (area under the curve 6.0) for 4–6 cycles during the induction period. Patients with controlled disease entered the maintenance period, continuing with CT-P16 or EU-bevacizumab as monotherapy until disease progression/intolerable toxicity. They were then followed up every 9 weeks until death or end of study. Outcomes were evaluated ≤3 years after the last patient enrollment.</div></div><div><h3>Results</h3><div>Of 689 patients receiving CT-P16 (<em>N</em> = 342) or EU-bevacizumab (<em>N</em> = 347), 499 (72.4 %) completed the induction period (CT-P16, <em>n</em> = 258 [75.4 %]; EU-bevacizumab, <em>n</em> = 241 [69.5 %]), 466 (67.6 %) initiated the maintenance period (CT-P16, <em>n</em> = 239 [69.9 %]; EU-bevacizumab, <em>n</em> = 227 [65.4 %]), and 389 (56.5 %) entered follow-up (CT-P16, <em>n</em> = 190 [55.6 %]; EU-bevacizumab, <em>n</em> = 199 [57.3 %]). Whole study ORRs were similar for CT-P16 (45.61 % [95 % confidence interval 40.34–50.89]) and EU-bevacizumab (46.11 % [95 % confidence interval 40.86–51.35]). Response duration, time to progression, progression-free survival, and overall survival were similar. No new safety signals were detected.</div></div><div><h3>Conclusions</h3><div>Long-term results of the CT-P16 3.1 study confirm equivalent efficacy of CT-P16 and EU-bevacizumab in patients with metastatic or recurrent non-squamous NSCLC.</div></div><div><h3>Trial registration number</h3><div>NCT03676192.</div></div><div><h3>Micro abstract</h3><div>Equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) was demonstrated in a phase 3 study of patients with metastatic or recurrent non-squamous NSCLC. Long-term findings in 689 patients confirmed equivalent efficacy of CT-P16 and EU-bevacizumab; objective response rates were 45.6 % and 46.1 %, respectively. Response duration, time to progression, progression-free survival, and overall survival were also similar.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100970"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dendrosomal Curcumin Nanoformulation induces apoptosis via Bax/Bcl-2 in human ovarian cancer OVCAR3 cells","authors":"Marziyeh Alizadeh Zarei ,&nbsp;Hossein Nikzad ,&nbsp;Zahra Shabani ,&nbsp;Hamed Haddad Kashani ,&nbsp;Elahe Seyed Hosseini","doi":"10.1016/j.ctarc.2025.100981","DOIUrl":"10.1016/j.ctarc.2025.100981","url":null,"abstract":"<div><h3>Introduction</h3><div>Curcumin (Cur), a yellow polyphenolic compound derived from the rhizome of turmeric, exhibits potent chemopreventive and chemotherapeutic properties. However, its clinical application as an anticancer agent is hindered by poor water solubility and low bioavailability. To overcome these limitations, the present study introduces a novel nanoformulation in which curcumin is effectively encapsulated within 142 nm spherical dendrosomes, which serve as a non-toxic nanocarrier.</div></div><div><h3>Methods</h3><div>The morphological changes in OVCAR3 ovarian cancer cells were assessed using both inverted light microscopy and fluorescence microscopy. Cell cycle distribution was analyzed by flow cytometry using the MultiCycler software. Cells were treated with dendrosomal curcumin (DNC), oxaliplatin (Oxa), or a combination of both for 48 hours. Protein expression levels were analyzed by western blotting using enhanced chemiluminescence (ECL) detection.</div></div><div><h3>Results</h3><div>Dendrosomal curcumin improves curcumin’s bioavailability and therapeutic potential in cancer treatment. Treatment with DNC and Oxa individually resulted in significant induction of apoptosis in OVCAR3 cells. The combination therapy further amplified this effect compared to either agent alone. Molecular analyses revealed upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 at both mRNA and protein levels, supporting the activation of apoptotic pathways.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that both DNC and Oxa induce apoptosis in OVCAR3 ovarian cancer cells through modulation of Bax and Bcl-2 expression. The enhanced efficacy observed in combination therapy highlights the therapeutic potential of DNC, in conjunction with conventional chemotherapeutics, as a promising strategy for ovarian cancer treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100981"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144887077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ERO1α regulates curcumin-induced autophagy via PI3K/AKT pathway","authors":"Dandan Huang ,&nbsp;Bolorchimeg Baldandorj ,&nbsp;Erdenezaya Odkhuu ,&nbsp;Egshiglen Amartuvshin ,&nbsp;Damdindorj Boldbaatar ,&nbsp;Hairong Guo ,&nbsp;Adilsaikhan Mendjargal","doi":"10.1016/j.ctarc.2025.100957","DOIUrl":"10.1016/j.ctarc.2025.100957","url":null,"abstract":"<div><h3>Objective</h3><div>Through comprehensive analysis of cisplatin-resistant HeLa cervical cancer cells, we reveal that curcumin exerts potent anti-cancer effects by modulating autophagic processes, and further identify Endoplasmic reticulum oxidoreductase 1-alpha (ERO1α) as a key regulator mediating this biological response.</div></div><div><h3>Methods</h3><div>Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8). The immunoblotting analysis measured the Phosphoinositide 3-Kinase/ Protein Kinase B (PI3K/AKT) pathway-related proteins, Microtubule-associated protein 1A/1B-light chain 3 (LC3II/I) ratio, and Beclin-1 expression. The cell migration ability was evaluated through a scratch assay.</div></div><div><h3>Results</h3><div>Curcumin significantly inhibits the proliferation and migration of cisplatin-resistant HeLa cells. It promotes autophagy in these cells, as shown by the upregulation of autophagy-related proteins Beclin-1 and LC3II/I. Curcumin also downregulates ERO1α expression, subsequently modulating the PI3K/AKT pathway. Interestingly, the overexpression of ERO1α or activation of PI3K negated the autophagy-promoting effects of curcumin, indicated by the absence of changes in autophagy-related proteins and phosphorylation levels of PI3K/AKT.</div></div><div><h3>Conclusions</h3><div>Our study provides compelling evidence that curcumin inhibits the proliferation and migration of cisplatin-resistant HeLa cells by promoting autophagy through the downregulation of ERO1α and inhibition of the PI3K/AKT pathway.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100957"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving fertility preservation for male cancer patients: A scoping review of barriers and facilitators","authors":"Ariana Orlić,&nbsp;Issam Alsamara,&nbsp;Martina Paric","doi":"10.1016/j.ctarc.2025.100976","DOIUrl":"10.1016/j.ctarc.2025.100976","url":null,"abstract":"<div><h3>Background</h3><div>Fertility preservation (FP) is an important aspect of cancer care for male patients of reproductive age; however, there is a lack of research on male experiences of FP. This scoping review aims to identify barriers and facilitators to FP among male cancer patients, based on both patient and healthcare provider/researcher perspectives.</div></div><div><h3>Method</h3><div>We conducted a scoping review following the Joanna Briggs Institute methodology and reported results according to the PRISMA-ScR checklist. We searched MEDLINE/PubMed, CINAHL, APA PsycInfo, and Web of Science, with supplemented hand-searching of the ESHRE website and reference lists. We included primary studies published in English (2001–2023) reporting on FP in male cancer patients. Findings were mapped to the Theoretical Domains Framework (TDF).</div></div><div><h3>Results</h3><div>A total of 56 studies met the inclusion criteria. Eleven TDF domains were applicable, with one additional domain, “Patient Characteristics”, added inductively. Among patients, the most frequently coded domains were “Social Influences”, “Goals, Beliefs about Capabilities”, and “Emotion”. For providers/researchers, key domains included “Environmental Context and Resources”, “Patient Characteristics” and “Knowledge”.</div></div><div><h3>Conclusion</h3><div>A combination of social, psychological, and contextual factors shapes barriers and facilitators to FP in male cancer patients. Addressing these barriers could improve male cancer patients’ quality of life and well-being during treatment and beyond. Recommendations include formalised FP care pathways with an educated, multidisciplinary team, which should be supported by concrete legal and ethical guidelines integrated in policy frameworks concerning cancer care. Applying the TDF can support the development of targeted, evidence-informed strategies to improve FP integration in cancer care.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100976"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144887121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive pan-cancer analysis identified NSD2 as a potential prognostic and diagnostic biomarker","authors":"Shuang Wang ,&nbsp;Tao Li","doi":"10.1016/j.ctarc.2025.100995","DOIUrl":"10.1016/j.ctarc.2025.100995","url":null,"abstract":"<div><div>NSD2 is a histone lysine N-methyltransferase that plays a crucial role in complex cancer biology. Despite mounting evidence highlighting the critical role of NSD2 in tumor progression and immunity, a comprehensive pan-cancer analysis of NSD2 has yet to be performed to determine whether NSD2 can be used as a viable biomarker, for cancer screening, prognostic prediction, and for the accurate design of therapeutic regimens for a variety of human malignancies. malignancies. This study was based on TCGA, TIMER2.0, cBioPortal, TCGA plot R software package and comprehensively investigated the expression of NSD2 in 33 different tumors, clinical phenotype, survival analysis, immune infiltration, genetic alterations, correlation with TMB and MSI, enrichment analysis and prognostic significance. The results showed that NSD2 was significantly overexpressed in most tumors and significantly correlated with low OS in different tumor types. Our findings suggest its potential oncogenic and epigenetic role. Amplification was the most common type of NSD2 variant. Immune infiltration analysis revealed a strong correlation between NSD2 and different immune cells. NSD2 was significantly associated with TMB and MSI in several cancers. Furthermore, enrichment analysis revealed associations between NSD2 and cell cycle and DNA repair pathways as well as various cellular functions. These findings suggest that NSD2 may serve as a potential prognostic biomarker and target for immunotherapy of various cancers.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100995"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1","authors":"M Sereno ,&nbsp;A Collazo-Lorduy ,&nbsp;Y Garitaonaindia ,&nbsp;D Gómez de Antonio ,&nbsp;J Baena Espinar ,&nbsp;C Aguado de la Rosa ,&nbsp;P Cruz Castellanos ,&nbsp;S Falagán Martínez ,&nbsp;LE Chara Valverde ,&nbsp;R López-Castro ,&nbsp;A López-Martin ,&nbsp;J Rubio-Pérez ,&nbsp;A Gómez Rueda ,&nbsp;C Traseira Puchol ,&nbsp;X Mielgo Rubio ,&nbsp;B Losada Vila ,&nbsp;J Rogado ,&nbsp;E Bernal Hertfelder ,&nbsp;L Gutiérrez Sainz ,&nbsp;JL Campo-Cañaveral ,&nbsp;E Casado Sáenz","doi":"10.1016/j.ctarc.2025.100910","DOIUrl":"10.1016/j.ctarc.2025.100910","url":null,"abstract":"<div><h3>Background</h3><div>The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.</div></div><div><h3>Methods</h3><div>From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.</div></div><div><h3>Results</h3><div>Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, <em>p</em> = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, <em>p</em> = 0.001) and FVC (+3.7 % vs. -0.7 %, <em>p</em> = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.</div></div><div><h3>Conclusions</h3><div>CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100910"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of different chemotherapies given to Nodular Lymphocyte Predominant Hodgkin Lymphoma patients: A retrospective study from Lahore, Pakistan","authors":"Namra Jabeen,&nbsp;Nazia Kanwal,&nbsp;Haroon Ibrahim,&nbsp;Aamir Amin","doi":"10.1016/j.ctarc.2025.100930","DOIUrl":"10.1016/j.ctarc.2025.100930","url":null,"abstract":"<div><div>Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare type of Hodgkin lymphoma. This retrospective study aims to find most efficient chemotherapy that gives high rates of Progression Free Survival (PFS) and overall survival (OS). In this study confirmed patients of NLPHL identified from different hospitals from 2011 to 2023. Clinical characteristics were collected from these patients to confirm NLPHL diagnosis. Eighty confirmed NLPHL patients were identified, and their median follow-up was 36 months. The median age of the participants was 35 years with minimum age of 2 years while maximum participant’s age of 70 years in which 26.1% were females while 73.8% were males. It was observed that surgery was the first line treatment given to 18.8% patients before chemotherapy and to 81.3% patients chemotherapy was the first line treatment. Patients’ chemotherapy treatments shows that 57.5% patients received ABVD, 16.3% patients with BEACOPP, while 8.8% patients received CHOP, 17.5% patients were given Rituximab-based or other treatments. According to Ann-Arbor stage*, 16.3% of the patients were of stage I, 36.3% of stage II, 27.5% of stage III and 20.0% of stage IV. Relapse was observed in 35% of the patients after chemotherapy treatment. In this study, the divergent characteristics of NLPHL treatments showed a comparatively good long-term prognosis. Mostly patients showed a good response to first line treatment. In this study, ABVD showed the best chemotherapy treatment with excellent outcomes. The overall survival demonstrated excellent initial survival rates within 5 years.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100930"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial for “Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer”","authors":"Shayan Sheikhmiri ,&nbsp;Mostafa Robatjazi ,&nbsp;Seyed Alireza Javadinia ,&nbsp;Sara Shenavaei Zare ,&nbsp;Iman Jalaimehr ,&nbsp;Reza Chaman","doi":"10.1016/j.ctarc.2025.100935","DOIUrl":"10.1016/j.ctarc.2025.100935","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100935"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","authors":"Davor Galusic ,&nbsp;Josip Batinic ,&nbsp;Ivan Krecak ,&nbsp;Barbara Dreta ,&nbsp;Delfa Radic Kristo ,&nbsp;Mario Pirsic ,&nbsp;Goran Rincic ,&nbsp;Jasminka Sincic-Petricevic ,&nbsp;Toni Valkovic ,&nbsp;Milan Vujcic ,&nbsp;Marin Simunic ,&nbsp;Karla Misura Jakobac ,&nbsp;Martina Sedinic Lacko ,&nbsp;Klara Brcic ,&nbsp;Vlatka Perisa ,&nbsp;Fran Petricevic ,&nbsp;Dragana Grohovac ,&nbsp;Hrvoje Holik ,&nbsp;Martina Moric Peric ,&nbsp;Ivan Zekanovic ,&nbsp;Sandra Basic-Kinda","doi":"10.1016/j.ctarc.2025.100912","DOIUrl":"10.1016/j.ctarc.2025.100912","url":null,"abstract":"<div><h3>Background</h3><div>Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia.</div></div><div><h3>Methods</h3><div>Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres.</div></div><div><h3>Results</h3><div>A total of 119 patients with RRMM were included; median age was 66 years (range 45–83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1–8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events.</div></div><div><h3>Conclusion</h3><div>This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100912"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer","authors":"Seung Ho Baek ,&nbsp;Soong June Bae ,&nbsp;Yoonwon Kook ,&nbsp;Yeona Cho ,&nbsp;Sung Gwe Ahn ,&nbsp;Jun Won Kim ,&nbsp;Ik Jae Lee ,&nbsp;Joon Jeong","doi":"10.1016/j.ctarc.2025.100925","DOIUrl":"10.1016/j.ctarc.2025.100925","url":null,"abstract":"<div><h3>Background</h3><div>Although the use of intraoperative radiotherapy (IORT) for accelerated partial breast irradiation is growing, there are not many studies on its effectiveness specifically in Asian population. In this study, we aimed to investigate the long-term oncologic outcomes of Korean patients who received IORT with low-energy X-ray as a tumor-bed boost.</div></div><div><h3>Methods</h3><div>We conducted phase II, prospective, single-arm trial to evaluate the local toxicity and oncologic outcomes in breast cancer patients receiving IORT with low-energy X-rays as a tumor-bed boost (NCT02213991). Patients underwent IORT as a tumor-bed boost with low-energy X-rays (20 Gy) followed by external beam radiotherapy for whole breast irradiation (46 Gy). Patients diagnosed with early-stage breast cancer or ductal carcinoma in situ who were suitable for lumpectomy were considered eligible. Kaplan-Meier analysis was used to assess oncologic outcomes with an extended follow-up period.</div></div><div><h3>Results</h3><div>A total of 194 patients underwent IORT between August 2014 and September 2016 according to the protocol outlined in our study. During the median follow-up of 85.6 months, 12 cases (6.19 %) of recurrence were reported, of which 4 (2.06 %) were reported ipsilateral breast tumor recurrence (IBTR) as the first recurrence event. The 5- and 8-year IBTR rates were both 2.1 % (95 % confidence intervals (CIs), 93.8 – 98.9). The 5-year loco-regional recurrence-free survival (LRRFS), recurrence-free survival (RFS), and overall survival (OS) rates were 97.37 %, 96.32 %, and 100 %, respectively.</div></div><div><h3>Conclusion</h3><div>We identified the oncologic safety of IORT with low-energy X-rays as a tumor-bed boost in Korean patients during an extended follow-up period.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100925"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}